Improved health-related quality of life in patients with recurrent Clostridioides difficile infection after treatment with faecal microbiota transplantation.

IF 2.3 Infectious diseases (London, England) Pub Date : 2025-03-01 Epub Date: 2024-10-26 DOI:10.1080/23744235.2024.2415694

Cecilia Magnusson, Elis Ölfvingsson, Henrik Hjortswang, Åse Östholm, Lena Serrander

{"title":"Improved health-related quality of life in patients with recurrent Clostridioides difficile infection after treatment with faecal microbiota transplantation.","authors":"Cecilia Magnusson, Elis Ölfvingsson, Henrik Hjortswang, Åse Östholm, Lena Serrander","doi":"10.1080/23744235.2024.2415694","DOIUrl":null,"url":null,"abstract":"Background: Clostridioides difficile is a major burden for both healthcare systems and the patients. Faecal microbiota transplantation (FMT) is becoming more common as a treatment since it reduces the risk of recurrent Clostridioides difficile infection (rCDI).Objectives: To evaluate how treatment with FMT is affecting the health-related quality of life (HRQoL) in patients with rCDI.Methods: A prospective observational cohort study was conducted where patients who were offered FMT as a treatment for rCDI were asked to fill in a questionnaire based on the Short Health Scale (SHS) and EuroQol 5-Dimensions 5-Levels (EQ-5D-5L) about their HRQoL before and after treatment.Results: Patients with rCDI had poor HRQoL, which improved following FMT.Conclusions: Since FMT cures, reduces the risk of new recurrences of CDI and improves the HRQoL of the patients, it should be offered as a treatment for patients with rCDI. Also, SHS is a useful and reliable instrument for measuring HRQoL in patients with rCDI.","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"239-246"},"PeriodicalIF":2.3000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious diseases (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23744235.2024.2415694","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/26 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Clostridioides difficile is a major burden for both healthcare systems and the patients. Faecal microbiota transplantation (FMT) is becoming more common as a treatment since it reduces the risk of recurrent Clostridioides difficile infection (rCDI).

Objectives: To evaluate how treatment with FMT is affecting the health-related quality of life (HRQoL) in patients with rCDI.

Methods: A prospective observational cohort study was conducted where patients who were offered FMT as a treatment for rCDI were asked to fill in a questionnaire based on the Short Health Scale (SHS) and EuroQol 5-Dimensions 5-Levels (EQ-5D-5L) about their HRQoL before and after treatment.

Results: Patients with rCDI had poor HRQoL, which improved following FMT.

Conclusions: Since FMT cures, reduces the risk of new recurrences of CDI and improves the HRQoL of the patients, it should be offered as a treatment for patients with rCDI. Also, SHS is a useful and reliable instrument for measuring HRQoL in patients with rCDI.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

粪便微生物群移植治疗后，复发性艰难梭菌感染患者与健康相关的生活质量得到改善。

背景：艰难梭菌是医疗系统和患者的主要负担。粪便微生物群移植（FMT）作为一种治疗方法正变得越来越普遍，因为它能降低艰难梭菌复发感染（rCDI）的风险：评估粪便菌群移植治疗如何影响艰难梭菌感染（rCDI）患者的健康相关生活质量（HRQoL）：方法：开展了一项前瞻性观察性队列研究，要求接受 FMT 治疗的 rCDI 患者在治疗前后填写一份基于简易健康量表（SHS）和欧洲量表（EQ-5D-5L）的有关其 HRQoL 的问卷：结果：rCDI 患者的 HRQoL 较差，但在 FMT 治疗后有所改善：结论：由于 FMT 可治愈 CDI，降低 CDI 复发风险，改善患者的 HRQoL，因此应作为一种治疗方法提供给 rCDI 患者。此外，SHS 是测量 rCDI 患者 HRQoL 的一种有用而可靠的工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Infectious diseases (London, England)

自引率

0.00%

发文量